Get started

Financials · SKIN

SkinHealth Systems Inc. (SKIN) financials

For the twelve months ended Sep 30, 2026, SkinHealth Systems Inc. reported $288.56M of revenue and -$18.29M of net income.

Revenue, TTM
$288.56M
Revenue growth, YoY
-4.4%
Net income, TTM
-$18.29M
Net margin
-6.3%
Free cash flow, TTM
$22.69M
EPS, diluted, TTM
-$2.00
Cash
$112.39M
P/S
0.38
Market cap
$109.1M
Annual revenue$300.79M
FY2019FY2025
Annual net income-$9.52M
FY2019FY2025
Annual free cash flow$37.18M
FY2019FY2025

SKIN revenue and earnings growth

SKIN revenueQ3 2026$69.17M

Quarter YoY
-2.1%
QoQ
-4.1%
FY YoY
-10.0%
5Y CAGR
+20.4%

SKIN revenue was $69.17M in fiscal Q3 2026 (ended Sep 30, 2026), down 2.1% from a year earlier and down 4.1% from the prior quarter. For the full fiscal 2025 it was $300.79M, down 10.0% from fiscal 2024. Compound annual growth was +20.4% over 5 years. It rose in 3 of the last 6 fiscal years.

SKIN net incomeQ3 2026-$888.0K

SKIN net income was -$888.0K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.03M a year earlier. For the full fiscal 2025 it was -$9.52M, compared with -$29.10M in fiscal 2024.

SKIN EPSQ3 2026-$0.14

SKIN diluted EPS was -$0.14 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.74 a year earlier. For the full fiscal 2025 it was -$3.20, compared with -$7.20 in fiscal 2024.

SKIN free cash flowQ3 2026$11.17M

Quarter YoY
+16.1%
QoQ
+397.8%
FY YoY
+141.8%

SKIN free cash flow was $11.17M in fiscal Q3 2026 (ended Sep 30, 2026), up 16.1% from a year earlier and up 397.8% from the prior quarter. For the full fiscal 2025 it was $37.18M, up 141.8% from fiscal 2024. Fiscal 2025 is the highest of the 7 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$300.79M$334.29M$397.99M$365.88M$260.09M$119.09M$166.62M
Cost of revenue$104.43M$152.00M$242.88M$117.10M$81.55M$51.89M$60.11M
Gross profit$196.36M$182.30M$155.11M$248.78M$178.54M$67.20M$106.51M
Research and development$5.63M$6.30M$10.10M$8.44M$8.20M$3.41M$4.61M
Selling, general and admin$117.95M$125.46M$131.43M$106.10M$98.69M$30.65M$26.66M
Operating income-$20.80M-$67.77M-$130.92M-$25.84M-$39.93M-$17.18M$13.46M
Interest expense$19.33M$10.41M$13.65M$13.39M$11.78M--
Pre-tax income-$5.94M-$29.55M-$101.89M$45.34M-$380.64M-$38.48M-$2.94M
Income tax$3.58M-$452.0K-$1.77M$1.11M-$1.88M-$9.31M-$1.30M
Net income-$9.52M-$29.10M-$100.12M$44.22M-$378.76M-$29.18M-$1.64M
EPS, basic-$1.60-$4.60-$15.20$6.00-$74.20-$17.00-$1.00
EPS, diluted-$3.20-$7.20-$15.20-$4.60-$74.20-$17.00-$1.00
Diluted shares6.8M7.1M6.6M7.4M5.1M1.7M1.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$232.67M$370.06M$523.02M$568.20M$901.89M$9.49M$7.31M
Receivables$21.74M$27.64M$54.70M$76.49M$46.82M$18.58M-
Inventory$48.01M$69.11M$91.32M$109.66M$35.26M$23.20M-
Current assets$309.52M$477.12M$698.25M$783.27M$1.00B$59.09M-
Goodwill$126.62M$123.50M$125.82M$124.59M$123.69M$98.53M$98.52M
Total assets$499.80M$685.68M$929.11M$1.00B$1.22B$222.84M-
Current liabilities$186.28M$68.15M$115.01M$71.71M$76.44M$30.93M-
Total debt-$552.20M-----
Total liabilities$438.75M$633.88M$869.72M$836.03M$916.51M$252.79M-
Shareholders' equity$61.06M$51.80M$59.39M$167.05M$298.03M-$30.57M-$1.21M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow$37.48M$16.13M$21.75M-$106.60M-$28.36M-$12.44M$1.73M
Capital expenditures$303.0K$756.0K$3.83M$10.85M$11.20M$3.50M$8.77M
Free cash flow$37.18M$15.38M$17.93M-$117.45M-$39.56M-$15.94M-$7.05M
Investing cash flow-$5.16M-$6.79M-$31.51M-$18.87M-$37.73M-$3.82M-$12.48M
Financing cash flow-$174.93M-$158.34M-$37.45M-$205.24M$959.03M$18.27M$14.58M
Share repurchases$0$0$30.16M$160.00M$0$154.0K$0
Stock-based compensation$14.82M$26.70M$22.54M$28.50M$12.42M$363.0K$103.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY-10.0%-16.0%8.8%40.7%118.4%-28.5%-
Gross margin65.3%54.5%39.0%68.0%68.6%56.4%63.9%
Operating margin-6.9%-20.3%-32.9%-7.1%-15.4%-14.4%8.1%
Net margin-3.2%-8.7%-25.2%12.1%-145.6%-24.5%-1.0%
Free cash flow margin12.4%4.6%4.5%-32.1%-15.2%-13.4%-4.2%
Return on equity-15.6%-56.2%-168.6%26.5%-127.1%--
Return on assets-1.9%-4.2%-10.8%4.4%-31.1%-13.1%-
Current ratio1.667.006.0710.9213.091.91-
Debt to equity-10.66-----

Source: XBRL data SkinHealth Systems Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Nov 5, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

SKIN peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
SKIN$288.56M-4.4%-$18.29M-6.3%$109.1M
SYK$26.30B+7.9%$3.62B13.8%$121.36B
MMM$25.25B+1.7%$3.54B14.0%$97.60B
BSX$21.07B+8.9%$3.50B16.6%$65.41B
BDX$23.25B+17.4%$941.00M4.0%$58.43B
MDLN$30.68B-$683.00M2.2%$55.45B
RMD$5.73B+9.0%$1.59B27.8%$33.55B
DXCM$5.10B+13.0%$991.00M19.4%$29.97B
WST$3.40B+12.6%$638.90M18.8%$28.76B

SKIN FAQ

9 questions
  • What is SKIN revenue?
    SkinHealth Systems Inc. (SKIN) reported $288.56M of revenue for the twelve months ended Sep 30, 2026. That is down 4.4% from the year before. Revenue for fiscal 2025 was $300.79M.
  • Is SKIN profitable?
    No. SkinHealth Systems Inc. reported a net loss of $18.29M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does SKIN have?
    SkinHealth Systems Inc. reported $112.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is SKIN revenue growing?
    SkinHealth Systems Inc.'s revenue changed -10.0% in fiscal 2025, to $300.79M. Its compound annual growth rate was +20.4% over 5 years.
  • What is SKIN gross margin?
    SkinHealth Systems Inc.'s gross profit was $193.96M on $288.56M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 67.2%.
  • What is SKIN free cash flow?
    SkinHealth Systems Inc. generated $22.69M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $23.58M less capital expenditures.
  • What is SKIN earnings per share?
    Diluted earnings per share were -$2.00 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did SKIN last report financial results?
    The latest statements here come from SkinHealth Systems Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this SKIN financial data come from?
    Quantisnow builds these statements from the structured XBRL data SkinHealth Systems Inc. files with the SEC. It is provided for information only and is not investment advice.